TY - JOUR
T1 - Chaperonin-GroEL as a Smart Hydrophobic Drug Delivery and Tumor Targeting Molecular Machine for Tumor Therapy
AU - Yuan, Yi
AU - Du, Chong
AU - Sun, Cuiji
AU - Zhu, Jin
AU - Wu, Shan
AU - Zhang, Yinlong
AU - Ji, Tianjiao
AU - Lei, Jianlin
AU - Yang, Yinmo
AU - Gao, Ning
AU - Nie, Guangjun
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China (31500814, 31730032, 21373067, and 51673051), the National Distinguished Young Scientists program (31325010), the Innovation Research Group of the National Natural Science Foundation (11621505), the Key Research Project of Frontier Science of the Chinese Academy of Sciences (QYZDJ-SSW-SLH022), and Beijing Municipal Science and Technology Commission (Z161100000116035). We thank the Tsinghua University Branch of the China National Center for Protein Sciences (Beijing) for the use of Cryo-EM facility. This work was also supported by Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, Chinese Academy of Sciences and K.C.WONG Foundation, CAS (Y7552911ZX).
Publisher Copyright:
© 2017 American Chemical Society.
PY - 2018/2/14
Y1 - 2018/2/14
N2 - The targeted delivery of hydrophobic therapeutic drugs to tumors is one of the major challenges in drug development. The use of natural proteins as drug delivery vehicles holds great promise due to various functionalities of proteins. In the current study, we exploited a natural protein, GroEL, which possesses a double layer cage structure, as a hydrophobic drug container, which is switchable by ATP binding to a hydrophilic status, to design a novel and intelligent hydrophobic drug delivery molecular machine with a controlled drug release profile. When loaded with the hydrophobic antitumor drug, Doxorubicin (Dox), GroEL was able to shield the drug from the aqueous phase of blood, releasing the drug once in the presence of a critical concentration of ATP at the tumor site. Unexpectedly, we found that GroEL has a specific affinity for the cell structural protein, plectin, which is expressed at abnormally elevated levels on the membranes of tumor cells but not in normal cells. This finding, in combination with the ATP sensitivity, makes GroEL a superior natural tumor targeting nanocarrier. Our data show that GroEL-Dox is able to effectively, and highly selectively, deliver the hydrophobic drug to fast growing tumors without overt adverse effects on the major organs. GroEL is therefore a promising drug delivery platform that can overcome the obstacles to hydrophobic drug targeting and delivery.
AB - The targeted delivery of hydrophobic therapeutic drugs to tumors is one of the major challenges in drug development. The use of natural proteins as drug delivery vehicles holds great promise due to various functionalities of proteins. In the current study, we exploited a natural protein, GroEL, which possesses a double layer cage structure, as a hydrophobic drug container, which is switchable by ATP binding to a hydrophilic status, to design a novel and intelligent hydrophobic drug delivery molecular machine with a controlled drug release profile. When loaded with the hydrophobic antitumor drug, Doxorubicin (Dox), GroEL was able to shield the drug from the aqueous phase of blood, releasing the drug once in the presence of a critical concentration of ATP at the tumor site. Unexpectedly, we found that GroEL has a specific affinity for the cell structural protein, plectin, which is expressed at abnormally elevated levels on the membranes of tumor cells but not in normal cells. This finding, in combination with the ATP sensitivity, makes GroEL a superior natural tumor targeting nanocarrier. Our data show that GroEL-Dox is able to effectively, and highly selectively, deliver the hydrophobic drug to fast growing tumors without overt adverse effects on the major organs. GroEL is therefore a promising drug delivery platform that can overcome the obstacles to hydrophobic drug targeting and delivery.
KW - ATP excitation
KW - Chaperonin
KW - GroEL
KW - hydrophobic drug delivery
KW - nanocarrier
KW - tumor targeting
UR - http://www.scopus.com/inward/record.url?scp=85042095717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042095717&partnerID=8YFLogxK
U2 - 10.1021/acs.nanolett.7b04307
DO - 10.1021/acs.nanolett.7b04307
M3 - Article
C2 - 29287145
AN - SCOPUS:85042095717
VL - 18
SP - 921
EP - 928
JO - Nano Letters
JF - Nano Letters
SN - 1530-6984
IS - 2
ER -